Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCWIBU)

Drug Name
BMS-3870032 Drug Info
Synonyms
SNS-032; BMS-387032; SNS 032; BMS 387032; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; SNS-032 (BMS-387032); N-(5-(((5-(tert-Butyl)oxazol-2-yl)methyl)thio)thiazol-2-yl)piperidine-4-carboxamide; N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide; UNII-9979I93686; N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; CHEMBL296468; SNS032; C17H24N4O2S2; BMS387032
Cross-matching ID
PubChem CID
3025986
ChEBI ID
CHEMBL296468
CAS Number
CAS 345627-80-7
VARIDT Drug ID
DR01721

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.37 0.00e+0 93/133 (69.92%) ATP6V0B;ATP6AP1;NDUFA4L2;...
Valine, leucine and isoleucine degradation 2.33 0.00e+0 42/48 (87.5%) BCAT1;ACADM;ECHS1;...
Lysosome 2.27 0.00e+0 115/128 (89.84%) LAPTM4B;CTSC;ATP6V0B;...
Propanoate metabolism 2.21 0.00e+0 30/34 (88.24%) ECHS1;HIBCH;DLD;...
Alanine, aspartate and glutamate metabolism 2.16 0.00e+0 27/37 (72.97%) ALDH5A1;GLUD2;GOT2;...
Citrate cycle (TCA cycle) 2.14 0.00e+0 30/30 (100%) DLD;IDH3A;MDH2;...
Fatty acid degradation 2.11 0.00e+0 40/43 (93.02%) ACADM;ECHS1;ALDH3A2;...
Rheumatoid arthritis 2.09 0.00e+0 78/93 (83.87%) CXCL8;CCL20;HLA-DQA1;...
Arginine and proline metabolism 2.09 0.00e+0 39/50 (78%) MAOA;CKB;ALDH3A2;...
Pentose phosphate pathway 2.03 2.90e-3 25/30 (83.33%) RPIA;PFKL;PFKM;...
Phagosome 2.01 2.64e-3 118/152 (77.63%) HLA-DQA1;ATP6V0B;ATP6AP1;...
Glycolysis / Gluconeogenesis 2.00 3.62e-3 56/67 (83.58%) PFKL;DLD;ALDH3A2;...
Retrograde endocannabinoid signaling 1.99 4.46e-3 118/148 (79.73%) ADCY7;PRKACB;MAPK1;...
ECM-receptor interaction 1.97 4.14e-3 80/88 (90.91%) COL6A1;COL6A3;COL1A2;...
Pyruvate metabolism 1.94 5.80e-3 41/47 (87.23%) DLD;ALDH3A2;ACAT1;...
Fatty acid elongation 1.93 5.44e-3 19/27 (70.37%) ACOT7;ECHS1;PPT1;...
Butanoate metabolism 1.92 5.12e-3 23/28 (82.14%) ALDH5A1;ECHS1;ACAT1;...
Purine metabolism 1.88 5.64e-3 102/129 (79.07%) ADCY7;GUK1;HPRT1;...
beta-Alanine metabolism 1.87 6.10e-3 25/30 (83.33%) ECHS1;HIBCH;ALDH3A2;...
Biosynthesis of unsaturated fatty acids 1.82 9.42e-3 21/27 (77.78%) ACOT7;SCP2;HSD17B4;...
Diabetic cardiomyopathy 1.81 1.04e-2 162/203 (79.8%) COL1A2;NDUFA4L2;NDUFA10;...
Glycine, serine and threonine metabolism 1.80 1.05e-2 31/40 (77.5%) MAOA;DLD;PGAM1;...
Glyoxylate and dicarboxylate metabolism 1.80 1.01e-2 23/30 (76.67%) DLD;ACAT1;MDH2;...
Tryptophan metabolism 1.78 1.21e-2 35/42 (83.33%) MAOA;ECHS1;DLD;...
Glycosaminoglycan degradation 1.76 1.33e-2 19/19 (100%) HEXA;GALNS;GNS;...
D-Glutamine and D-glutamate metabolism 1.71 2.01e-2 5/5 (100%) GLUD2;GLUD1;DGLUCY;...
Cell adhesion molecules 1.69 2.09e-2 118/148 (79.73%) SDC2;NRCAM;HLA-DQA1;...
Vibrio cholerae infection 1.69 2.07e-2 44/50 (88%) ATP6V0B;ATP6AP1;PRKACB;...
Complement and coagulation cascades 1.68 2.25e-2 76/85 (89.41%) A2M;CFI;CD59;...
Glutathione metabolism 1.68 2.22e-2 43/57 (75.44%) GGT1;GPX3;GGCT;...
Endometrial cancer -1.67 3.91e-2 56/58 (96.55%) KRAS;SOS1;PTEN;...
Cytosolic DNA-sensing pathway -1.67 4.27e-2 52/63 (82.54%) POLR3D;DDX58;CXCL10;...
Chronic myeloid leukemia -1.70 3.28e-2 72/76 (94.74%) RAF1;GADD45G;SMAD4;...
Prostate cancer -1.71 3.43e-2 93/97 (95.88%) PDPK1;CREB1;RAF1;...
Small cell lung cancer -1.73 2.68e-2 90/92 (97.83%) RELA;LAMB3;BIRC3;...
Spliceosome -1.84 5.75e-3 101/150 (67.33%) AQR;TCERG1;SYF2;...
Signaling pathways regulating pluripotency of stem cell... -1.85 6.70e-3 110/143 (76.92%) BMI1;ID3;HOXD1;...
Transcriptional misregulation in cancer -1.87 8.04e-3 158/192 (82.29%) TLX3;MAF;EYA1;...
mRNA surveillance pathway -1.88 5.03e-3 71/98 (72.45%) CSTF2T;PPP2R3C;CSTF3;...
FoxO signaling pathway -1.95 0.00e+0 118/131 (90.08%) KRAS;BCL6;SOS1;...
Cell cycle -2.06 0.00e+0 110/124 (88.71%) PTTG1;CDC6;CUL1;...
MicroRNAs in cancer -2.09 0.00e+0 146/310 (47.1%) THBS1;BRCA1;MET;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 BRD4 (-) 1 CVCL_SF59 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 3H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Peripheral blood
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
LNCaP CVCL_0395 Homo sapiens 0.04uM - 10uM 3H, 24H
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 24H